CDKN2A (cyclin dependent
dependent Kinase 4 (INK4) family of proteins which also includes p15
p19INK4D. The INK4 proteins are roughly 40% homologous to one another, but individual members are highly conserved across species. Family members have in common a structural motif: a series of ankyrin repeats responsible for interaction with cyclin kinases 4/6 (CDK4/6).CDKN2A
by three exons: 1α, 2 and 3 (Fig.
Fig. 1.9 CDKN2A NM_000077.4 MapViewer representation
transcription verse. Blu bars show exons and red bars represent gene translation. Modified from NCBI MapViewer
http://www.ncbi.nlm.nih.gov/gene/1029
ARF promotes the sumoylation of its binding partners
ARF can promote the conjugation of the small ubiquitin-like protein SUMO
partners, including Mdm2 and B23. Sumoylation is analogous to ubiquitination, and is the process by which the SUMO protein is conjugated to a target protein. The effects of this modification are target specific and include control of protein stability, formation of subnuclear structures and regulation of transcription factor activities. The diverse functional consequences of sumoylation provide a possible explanation for the versatility of ARF downstream effects. Although, ARF can promote sumoylation in vivo, the biological impact of target sumoylation has not been demonstrated for ARF binding partners and sumoylation sites on these proteins remain unidentified. However, the fact that a subset of melanoma-associated p14ARF
, suggests that sumoylation may provide a mechanism for the diverse suppressor protein 38.
INK4A
ependent kinase inhibitor 2A) is a member of the inase 4 (INK4) family of proteins which also includes p15
. The INK4 proteins are roughly 40% homologous to one another, but individual members are highly conserved across species. Family members have in common a structural motif: a series of ankyrin repeats responsible for interaction with cyclin
CDKN2A gene encompasses 6.6 kb and is encoded, how previously said,
Fig. 1. 9).
_000077.4 MapViewer representation. Green bar shows the length and the gene
Blu bars show exons and red bars represent gene translation. Modified from NCBI MapViewer
m.nih.gov/gene/1029.
31 like protein SUMO-1 to its binding partners, including Mdm2 and B23. Sumoylation is analogous to ubiquitination, and is the process by which the SUMO protein is conjugated to a target protein. The effects of this nd include control of protein stability, formation of subnuclear structures and regulation of transcription factor activities. The diverse functional consequences of sumoylation provide a possible explanation for the versatility of ARF downstream effects. , the biological impact of target sumoylation has not been demonstrated for ARF binding partners and sumoylation sites on these proteins remain
ARF
mutations failed to , suggests that sumoylation may provide a mechanism for the diverse
) is a member of the INhibitor of cyclin- inase 4 (INK4) family of proteins which also includes p15INK4B, p18INK4C and . The INK4 proteins are roughly 40% homologous to one another, but individual members are highly conserved across species. Family members have in common a basic structural motif: a series of ankyrin repeats responsible for interaction with cyclin-dependent gene encompasses 6.6 kb and is encoded, how previously said,
Green bar shows the length and the gene Blu bars show exons and red bars represent gene translation. Modified from NCBI MapViewer
The human protein comprises 156 amino acids with a molecular weight of ~15.8kD. Its structure consists of repeated ‘ankyrin’ subunits containing two antiparallel helices and a loop, creating a cleft that binds CDK4 or CDK6
each β-hairpin loop are exposed to the cdk binding site; helix 2 and some loop residues provide structural support (Fig. 1.10)55
Fig. 1.10 Structural models of p16
the right) of the p16 structure, while
b show in purple the aminoacids in the binding cleft that contact CDK6. In
ribbon, and the molecule is viewed down the axis of the cleft. Modified from
CDKN2A expression levels are low in normal tissue. Following controversy concerning the cellular localization of p16 it has recently been shown that p16 can be expressed in both the nuclear and cytoplasmic compartments and that both nuclear and cytoplasmic p16 forms complexes with CDK4 and CDK6
appears predominantly in just one. p16 is upregulated in cells during in consistent with a role in ageing. Expression of p16 is often lost during progressi
INK4 binding to CDK4/6 inhibits its kinase activity and thereby arrests progression through the cell cycle in mid-late G1 (Fig
association with CDK4/6, shifting the CDK4/6 k
instead of active complexes with cyclin D. Inhibition of CDK4/6 kinase activity prevents pRB phosphorylation leading to restraint of E2F transactivation of the expression of genes important The human protein comprises 156 amino acids with a molecular weight of ~15.8kD. Its structure consists of repeated ‘ankyrin’ subunits containing two antiparallel helices and a loop, creating a
CDK6. The first helix of each pair and the last several aminoacids of
hairpin loop are exposed to the cdk binding site; helix 2 and some loop residues provide
55
.
models of p16. Images a, on the left shows the front (binding cleft, helices to the left, loops to
the right) of the p16 structure, while b, on the right, shows the back (helices to the right) of the p16 structure. s in the binding cleft that contact CDK6. In b, the p16 backbone is rendered as a ribbon, and the molecule is viewed down the axis of the cleft. Modified from M S Greenblatt, Oncogene, 2003
levels are low in normal tissue. Following controversy concerning the cellular localization of p16 it has recently been shown that p16 can be expressed in both the nuclear and cytoplasmic compartments and that both nuclear and cytoplasmic p16 forms
CDK6. Cytoplasmic p16 occurs in two forms whilst nuclear p16
appears predominantly in just one. p16 is upregulated in cells during in consistent with a role in ageing. Expression of p16 is often lost during progressi
INK4 binding to CDK4/6 inhibits its kinase activity and thereby arrests progression through the late G1 (Fig. 1.11). Induction of p16 leads to a competition with D
association with CDK4/6, shifting the CDK4/6 kinases to inactive complexes containing p16 instead of active complexes with cyclin D. Inhibition of CDK4/6 kinase activity prevents pRB phosphorylation leading to restraint of E2F transactivation of the expression of genes important 32 The human protein comprises 156 amino acids with a molecular weight of ~15.8kD. Its structure consists of repeated ‘ankyrin’ subunits containing two antiparallel helices and a loop, creating a helix of each pair and the last several aminoacids of hairpin loop are exposed to the cdk binding site; helix 2 and some loop residues provide
, on the left shows the front (binding cleft, helices to the left, loops to , on the right, shows the back (helices to the right) of the p16 structure. a and , the p16 backbone is rendered as a M S Greenblatt, Oncogene, 2003 55.
levels are low in normal tissue. Following controversy concerning the cellular localization of p16 it has recently been shown that p16 can be expressed in both the nuclear and cytoplasmic compartments and that both nuclear and cytoplasmic p16 forms . Cytoplasmic p16 occurs in two forms whilst nuclear p16 appears predominantly in just one. p16 is upregulated in cells during in vitro senescence consistent with a role in ageing. Expression of p16 is often lost during progression of a tumour. INK4 binding to CDK4/6 inhibits its kinase activity and thereby arrests progression through the
). Induction of p16 leads to a competition with D-cyclins for inases to inactive complexes containing p16 instead of active complexes with cyclin D. Inhibition of CDK4/6 kinase activity prevents pRB phosphorylation leading to restraint of E2F transactivation of the expression of genes important
for entry into S-phase (Fig. signal to cause a cell cycle arrest.
Fig. 1.11 p16INK4A /pRB pathways. p16
that phosphorylate, and therefore inactivate, RB during the mid
Hyperphosphorylated pRB dissociates from E2F1 trancription factor enabling transcription of S as myc, as well as ARF.
In the absence of pRB, forced induction of p16 does
many tumors that retain p16 expression, especially gliomas, other alterations occur in the p16 cyclinD-CDK4-pRB pathway: loss of pRB expression or overexpression of CDK4 or cyclin D1. A negative feedback loop exists between pRB and p16: transcription of
Therefore, it is not surprising that cells with inactive pRB frequently have elevated levels of expression, although in this setting p16 becomes ineffective in
According to repository data into (https://biodesktop.uvm.edu/perl/p16
the majority of mutations identified so far in mutations affect either p16 alone or both p16 and
1.11). The expression of pRB is essential for transducing p16’s signal to cause a cell cycle arrest.
. p16INK4A inhibits the complex between cyclin-dependent kinase 4/6 and cyclin D re inactivate, RB during the mid-late G1 phase of the cell cycle. Hyperphosphorylated pRB dissociates from E2F1 trancription factor enabling transcription of S
In the absence of pRB, forced induction of p16 does not cause cell cycle arrest. As a result, in many tumors that retain p16 expression, especially gliomas, other alterations occur in the p16
pRB pathway: loss of pRB expression or overexpression of CDK4 or cyclin D1. ists between pRB and p16: transcription of p16
Therefore, it is not surprising that cells with inactive pRB frequently have elevated levels of expression, although in this setting p16 becomes ineffective in restraining cell prolife
According to repository data into UVM BioDesktop-CDKN2a Database Project
https://biodesktop.uvm.edu/perl/p16 and http://atlasgeneticsoncology.org/Genes/CDKN2aID146.html
entified so far in CDKN2A are located in exons 1a and 2. These mutations affect either p16 alone or both p16 and p14ARF and appear to be associated solely with 33 The expression of pRB is essential for transducing p16’s
dependent kinase 4/6 and cyclin D late G1 phase of the cell cycle. Hyperphosphorylated pRB dissociates from E2F1 trancription factor enabling transcription of S-phase genes, such
not cause cell cycle arrest. As a result, in many tumors that retain p16 expression, especially gliomas, other alterations occur in the p16-
pRB pathway: loss of pRB expression or overexpression of CDK4 or cyclin D1. p16 is repressed by pRB. Therefore, it is not surprising that cells with inactive pRB frequently have elevated levels of p16
restraining cell proliferation 56. CDKN2a Database Project
http://atlasgeneticsoncology.org/Genes/CDKN2aID146.html) are located in exons 1a and 2. These and appear to be associated solely with
susceptibility to melanoma. A small number of mutations have been identified in exon 1b which appear to affect p14ARF alone.
Germline mutations affecting the
melanoma-astrocytoma syndrome families. Concurrent loss of both p14 and p16 may therefore be responsible for the development of
deletion affecting the p14ARF p16 function suggesting abnormal According to COSMIC somatic
sporadic melanoma and around 22% of tumours of the central nervous system dependent on tumour type.
(http://atlasgeneticsoncology.org /